KD Logo

CRISPR Therapeutics AG [CRSP] Insider Activity: An Update for Investors

CRISPR Therapeutics AG’s recent filing unveils that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $1.17 million on Apr 15 ’24. In the deal valued at $59.91 per share,19,582 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 208,122 shares worth roughly $12.49 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Kulkarni Samarth sold 20,000 shares, generating $1,449,628 in total proceeds. Upon selling the shares at $72.48, the Chief Executive Officer now owns 208,122 shares.

Before that, Prasad Raju sold 3,524 shares. CRISPR Therapeutics AG shares valued at $256,160 were divested by the Chief Financial Officer at a price of $72.69 per share. As a result of the transaction, Prasad Raju now holds 6,476 shares, worth roughly $0.39 million.

Wolfe Research initiated its CRISPR Therapeutics AG [CRSP] rating to a Peer perform in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who decreased its forecast for the stock in mid December from “a Market perform” to “an Underperform”. Cantor Fitzgerald also remained covering CRSP and has decreased its forecast on October 17, 2023 with a “Neutral” recommendation from previously “an Overweight” rating. Mizuho started covering the stock on September 27, 2023. It rated CRSP as “a Buy”.

Price Performance Review of CRSP

On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 3.66% to $59.99. Over the last five days, the stock has gained 4.97%. CRISPR Therapeutics AG shares have fallen nearly -4.17% since the year began. Nevertheless, the stocks have fallen -4.44% over the past one year. While a 52-week high of $91.10 was reached on 02/22/24, a 52-week low of $37.55 was recorded on 05/10/24. SMA at 50 days reached $57.40, while 200 days put it at $59.91. A total of 1.1 million shares were traded, compared to the trading of 0.97 million shares in the previous session.

Levels Of Support And Resistance For CRSP Stock

The 24-hour chart illustrates a support level at 57.83, which if violated will result in even more drops to 55.68. On the upside, there is a resistance level at 61.11. A further resistance level may holdings at 62.24. The Relative Strength Index (RSI) on the 14-day chart is 58.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.70, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 3.48%. Stochastics %K at 87.26% indicates the stock is a selling.

Most Popular